Contact this trialFirst, we need to learn more about you.
Bcl-2 inhibitor
Osimertinib + Navitoclax for Lung Cancer
Recruiting1 awardPhase 1
Pittsburgh, Pennsylvania
This trial studies the side effects and best dose of osimertinib and navitoclax when given together to treat patients with EGFR-positive non-small cell lung cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.